Benjamin Lightburn

Cannabis enthusiasts and industry insiders alike will find the latest episode of Benzinga's Cannabis Insider show both informative and engaging. In this episode, co-hosts Javier Hasse and Elliot Lane interview Benjamin Lightburn, the CEO and co-founder of Filament Health (OTCQB: FLHLF), a...

(Part three of a three-part series) See previous stories: EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans EXCLUSIVE: The Psychedelics Debate Is 'Raging' As Filament Debuts Ayahuasca Pill One of the concerns around what is commonly known as natural ...

Part two of a three-part series. Previous story: Standardized Ayahuasca Pill Is Officially Here, Feast Yourself With The Exclusive Details & Insights When it comes to the ayahuasca pill, Filament Health (OTCMTKS: FLHLF) CEO Ben Lightburn says the product won’t just be for the...

Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Currently in the form of a pill, the compound was conceived by Vancouver, BC-based natural drug development company Filament Health (OTCMKTS: FLHLF). During the development...

Clinical-stage natural psychedelics company Filament Health Corp. (OTCQB: FLHLF) announced it will start providing patients with doses of the first FDA-approved study directly administering psilocin and psilocybin derived from mushrooms, as opposed to manufactured synthetic...

Filament Health Corp. (OTCQB: FLHLF) and Jaguar Health, Inc. (NASDAQ: JAGX) have signed a letter of intent for a collaboration agreement. The deal would allow for the extension of both companies’ skillsets towards creating pharmaceutical-grade, standardized drug candidates for diagnoses such...

Psychedelic drug discovery company Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) obtained FDA approval to start the first clinical trial using naturally-sourced psychedelic substances.   Filament revealed that this authorization is the first for the direct administration of psilocin,...